Download MendeleyStructure-Based Design of a Highly Potent Dual-Competitive FTO Inhibitor for Targeted m 6 A Demethylase Inhibition in AML.
Zhang, X., Wang, Z., Xie, X., Liu, G., Dong, Z., Yang, C.G.(2025) J Med Chem 68: 22779-22798
- PubMed: 41190354 Search on PubMed
- DOI: https://doi.org/10.1021/acs.jmedchem.5c01738
- Primary Citation Related Structures:
9VG4 - PubMed Abstract:
Fat mass and obesity-associated protein (FTO), an Fe 2+ /2-oxoglutarate ( 2-OG )-dependent RNA demethylase, removes N 6 -methyladenosine (m 6 A) modification. FTO is overexpressed in AML, promoting pathogenesis through c-Myc upregulation. Using fragment linking of meclofenamic acid ( MA ) and 2-OG mimetics, we developed 8a , a substrate/ 2-OG dual-competitive FTO inhibitor. 8a substantially inhibits FTO demethylation, exceeding its constituent fragments' activity, with high selectivity over ALKBH3 and ALKBH5. 2-OG competition assay and docking confirm simultaneous occupation of substrate and 2-OG pockets, although the cocrystal structure revealed a different binding site. To circumvent the limitation of poor cellular permeability of 8a , we synthesized the prodrug ester 8a-1 , which suppressed AML cell viability, reduced m 6 A levels, downregulated c-Myc and CEBPA, and upregulated ASB2 and RARA. It has also shown obvious tumor-inhibiting efficacy at the animal level. 8a represents a highly potent FTO inhibitor with therapeutic potential, providing a framework for future development.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
Organizational Affiliation:
